Positive results in Phase IIb clinical trial struck by oral insulin innovation drug ORMD-0801

recently,(http://("Tianmai Bio"),) of Hefei Tianmai Biotech Development LimitedCompany ("Tianmai Bio") and Israel's OramdPharmaceutical(http://"Alamd")Company ("Oramd"), jointly developed oral insulin creationnew drug(http://ORMD-0801 announced the results of active phase IIb clinicaltrial(http://resultsParticipating in the ORMD-0801 Phase IIb clinical trial were treated by stubborn diabetics who were not effective in taking oral anti-sugar drugs (single, or two-drug, or three-drug combination)According to the results of the trial, after 3 months of daily oral insulin capsules, the patient's blood sugar decreased significantly and the weight was controlledWhile the results showed good effect on sugar reduction, the results showed excellent safety characteristics, no serious adverse events associated withdrug(http://, and no increase dysplasia eventsSpecifically, this placebo-controlled, double-blind, randomized, 90-day dose range IIb phase trial in patients with poor oral anti-sugar treatment was evaluated when ORMD-0801 was administered with different treatment options within the dose range, from baseline to 12 weeks of the primary therapeutic end of HbA1c reduction, as well as the end of safetyIn this trial, patients who were randomly treated with ORMD-0801 once a day reached the primary endpoint, with an average decrease of 0.6% in Hb A1c than baseline levels, or an average decrease of 0.54% (p value s 0.036) for Hb A1c after correction to the placeboHbA1c decreased by an average of 0.54%, a data that reflects clinical significance for patients and indicates improved blood sugar control, thereby reducing the risk of diabetes-related complications